IDO downregulation induces sensitivity to pemetrexed, gemcitabine, FK866, and methoxyamine in human cancer cells

PLoS ONE

Volumn 10, Issue 11, 2015, Pages

  Vareki, Saman Maleki ^a,b   Chen, Di ^a   Di Cresce, Christine ^a,b   Ferguson, Peter J ^a,b   Figueredo, Rene ^b   Pampillo, Macarena ^b   Rytelewski, Mateusz ^a,b   Vincent, Mark ^a,b   Min, Weiping ^a   Zheng, Xiufen ^a   Koropatnick, James ^a,b  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

^b LAWSON HEALTH RESEARCH INSTITUTE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA2 PROTEIN; DAPORINAD; FLOXURIDINE; GEMCITABINE; INDOLEAMINE 2,3 DIOXYGENASE; INDOLEAMINE 2,3 DIOXYGENASE 1; METHOXYAMINE; PEMETREXED; RECOMBINANT GAMMA INTERFERON; THYMIDYLATE SYNTHASE; UNCLASSIFIED DRUG; ACRYLAMIDE DERIVATIVE; DEOXYCYTIDINE; HYDROXYLAMINE; N-(4-(1-BENZOYLPIPERIDIN-4-YL)BUTYL)-3-(PYRIDIN-3-YL)ACRYLAMIDE; NICOTINAMIDE ADENINE DINUCLEOTIDE; PIPERIDINE DERIVATIVE; SMALL INTERFERING RNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFICACY; DRUG SENSITIVITY; DRUG SENSITIZATION; EXCISION REPAIR; HUMAN; HUMAN CELL; LUNG ADENOCARCINOMA; LUNG CANCER CELL LINE; MOLECULARLY TARGETED THERAPY; MOUSE; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PROTEIN EXPRESSION; PROTEIN FUNCTION; TUMOR GROWTH; ANALOGS AND DERIVATIVES; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL CLONE; DNA REPAIR; DRUG EFFECTS; DRUG RESISTANCE; DRUG SCREENING; ENZYME INDUCTION; GENE SILENCING; METABOLISM; SCID MOUSE; TUMOR CELL LINE;

ACRYLAMIDES; ANIMALS; BRCA2 PROTEIN; CELL LINE, TUMOR; CLONE CELLS; DEOXYCYTIDINE; DNA REPAIR; DOWN-REGULATION; DRUG RESISTANCE, NEOPLASM; ENZYME INDUCTION; FLOXURIDINE; GENE KNOCKDOWN TECHNIQUES; HUMANS; HYDROXYLAMINES; INDOLEAMINE-PYRROLE 2,3,-DIOXYGENASE; MICE, SCID; NAD; PEMETREXED; PIPERIDINES; RNA, SMALL INTERFERING; THYMIDYLATE SYNTHASE; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84957581704     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0143435     Document Type: Article

References (45)

1. Munn DH, Mellor AL (2013) Indoleamine 2,3 dioxygenase and metabolic control of immune responses. Trends Immunol 34: 137-143. doi: 10.1016/j.it.2012.10.001 PMID: 23103127
2. Sugimoto H, Oda S, Otsuki T, Hino T, Yoshida T, Shiro Y (2006) Crystal structure of human indoleamine 2,3-dioxygenase: catalytic mechanism of O2 incorporation by a heme-containing dioxygenase. Proc Natl Acad Sci U S A 103: 2611-2616. PMID: 16477023
3. Sahm F, Oezen I, Opitz CA, Radlwimmer B, von Deimling A, Ahrendt T, et al. (2013) The endogenous tryptophan metabolite and NAD+ precursor quinolinic acid confers resistance of gliomas to oxidative stress. Cancer Res 73: 3225-3234. doi: 10.1158/0008-5472.CAN-12-3831 PMID: 23548271
4. Maleki Vareki S, Rytelewski M, Figueredo R, Chen D, Ferguson PJ, Vincent M, et al. (2014) Indoleamine 2,3-dioxygenase mediates immune-independent human tumor cell resistance to olaparib, gamma radiation, and cisplatin. Oncotarget 5: 2778-2791. PMID: 24784564
5. Yoshida R, Urade Y, Tokuda M, Hayaishi O (1979) Induction of indoleamine 2,3-dioxygenase in mouse lung during virus infection. Proc Natl Acad Sci U S A 76: 4084-4086. PMID: 291064
6. Robinson CM, Hale PT, Carlin JM (2005) The role of IFN-gamma and TNF-alpha-responsive regulatory elements in the synergistic induction of indoleamine dioxygenase. J Interferon Cytokine Res 25: 20-30. PMID: 15684619
7. Uyttenhove C, Pilotte L, Theate I, Stroobant V, Colau D, Parmentier N, et al. (2003) Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase. Nat Med 9: 1269-1274. PMID: 14502282
8. Munn DH, Mellor AL (2007) Indoleamine 2,3-dioxygenase and tumor-induced tolerance. J Clin Invest 117: 1147-1154. PMID: 17476344
9. Pan K, Wang H, Chen MS, Zhang HK, Weng DS, Zhou J, et al. (2008) Expression and prognosis role of indoleamine 2,3-dioxygenase in hepatocellular carcinoma. J Cancer Res Clin Oncol 134: 1247-1253. doi: 10.1007/s00432-008-0395-1 PMID: 18438685
10. Smith C, Chang MY, Parker KH, Beury DW, DuHadaway JB, Flick HE, et al. (2012) IDO is a nodal pathogenic driver of lung cancer and metastasis development. Cancer Discov 2: 722-735. doi: 10.1158/2159-8290.CD-12-0014 PMID: 22822050
11. Mansfield AS, Heikkila PS, Vaara AT, von Smitten KA, Vakkila JM, Leidenius MH (2009) Simultaneous Foxp3 and IDO expression is associated with sentinel lymph node metastases in breast cancer. BMC Cancer 9: 231. doi: 10.1186/1471-2407-9-231 PMID: 19604349
12. Brandacher G, Perathoner A, Ladurner R, Schneeberger S, Obrist P, Winkler C, et al. (2006) Prognostic value of indoleamine 2,3-dioxygenase expression in colorectal cancer: effect on tumor-infiltrating T cells. Clin Cancer Res 12: 1144-1151. PMID: 16489067
13. Inaba T, Ino K, Kajiyama H, Yamamoto E, Shibata K, Nawa A, et al. (2009) Role of the immunosuppressive enzyme indoleamine 2,3-dioxygenase in the progression of ovarian carcinoma. Gynecol Oncol 115: 185-192. doi: 10.1016/j.ygyno.2009.07.015 PMID: 19665763
14. Holmgaard RB, Zamarin D, Munn DH, Wolchok JD, Allison JP (2013) Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4. J Exp Med 210: 1389-1402. doi: 10.1084/jem.20130066 PMID: 23752227
15. Muller AJ, DuHadaway JB, Donover PS, Sutanto-Ward E, Prendergast GC (2005) Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy. Nat Med 11: 312-319. PMID: 15711557
16. Creelan BC, Antonia S, Bepler G, Garrett TJ, Simon GR, Soliman HH (2013) Indoleamine 2,3-dioxygenase activity and clinical outcome following induction chemotherapy and concurrent chemoradiation in Stage III non-small cell lung cancer. Oncoimmunology 2: e23428. PMID: 23802083
17. Okamoto A, Nikaido T, Ochiai K, Takakura S, Saito M, Aoki Y, et al. (2005) Indoleamine 2,3-dioxygenase serves as a marker of poor prognosis in gene expression profiles of serous ovarian cancer cells. Clin Cancer Res 11: 6030-6039. PMID: 16115948
18. Sim SH, Ahn YO, Yoon J, Kim TM, Lee SH, Kim DW, et al. (2012) Influence of chemotherapy on nitric oxide synthase, indole-amine-2,3-dioxygenase and CD124 expression in granulocytes and monocytes of non-small cell lung cancer. Cancer Sci 103: 155-160. doi: 10.1111/j.1349-7006.2011.02158.x PMID: 22107611
19. Kim MY, Zhang T, Kraus WL (2005) Poly(ADP-ribosyl)ation by PARP-1: 'PAR-laying' NAD+ into a nuclear signal. Genes Dev 19: 1951-1967. PMID: 16140981
20. Okano S, Lan L, Caldecott KW, Mori T, Yasui A (2003) Spatial and temporal cellular responses to single-strand breaks in human cells. Mol Cell Biol 23: 3974-3981. PMID: 12748298
21. Sharma RA, Dianov GL (2007) Targeting base excision repair to improve cancer therapies. Mol Aspects Med 28: 345-374. PMID: 17706275
22. Dianov GL (2011) Base excision repair targets for cancer therapy. Am J Cancer Res 1: 845-851. PMID: 22016832
23. Di Cresce C, Figueredo R, Ferguson PJ, Vincent MD, Koropatnick J (2011) Combining small interfering RNAs targeting thymidylate synthase and thymidine kinase 1 or 2 sensitizes human tumor cells to 5-fluorodeoxyuridine and pemetrexed. J Pharmacol Exp Ther 338: 952-963. doi: 10.1124/jpet.111. 183178 PMID: 21673071
24. Pittelli M, Formentini L, Faraco G, Lapucci A, Rapizzi E, Cialdai F, et al. (2010) Inhibition of nicotinamide phosphoribosyltransferase: cellular bioenergetics reveals a mitochondrial insensitive NAD pool. J Biol Chem 285: 34106-34114. doi: 10.1074/jbc.M110.136739 PMID: 20724478
25. Galvani E, Peters GJ, Giovannetti E (2011) Thymidylate synthase inhibitors for non-small cell lung cancer. Expert Opin Investig Drugs 20: 1343-1356. doi: 10.1517/13543784.2011.617742 PMID: 21905922
26. Bulgar AD, Weeks LD, Miao Y, Yang S, Xu Y, Guo C, et al. (2012) Removal of uracil by uracil DNA glycosylase limits pemetrexed cytotoxicity: overriding the limit with methoxyamine to inhibit base excision repair. Cell Death Dis 3: e252. doi: 10.1038/cddis.2011.135 PMID: 22237209
27. Lau JP, Weatherdon KL, Skalski V, Hedley DW (2004) Effects of gemcitabine on APE/ref-1 endonuclease activity in pancreatic cancer cells, and the therapeutic potential of antisense oligonucleotides. Br J Cancer 91: 1166-1173. PMID: 15316562
28. Fischer JA, Muller-Weeks S, Caradonna SJ (2006) Fluorodeoxyuridine modulates cellular expression of the DNA base excision repair enzyme uracil-DNA glycosylase. Cancer Res 66: 8829-8837. PMID: 16951200
29. Ferguson PJ, Collins O, Dean NM, DeMoor J, Li CS, Vincent MD, et al. (1999) Antisense down-regulation of thymidylate synthase to suppress growth and enhance cytotoxicity of 5-FUdR, 5-FU and Tomudex in HeLa cells. Br J Pharmacol 127: 1777-1786. PMID: 10482907
30. Yoshida K, Miki Y (2004) Role of BRCA1 and BRCA2 as regulators of DNA repair, transcription, and cell cycle in response to DNA damage. Cancer Sci 95: 866-871. PMID: 15546503
31. Houtkooper RH, Canto C, Wanders RJ, Auwerx J (2010) The secret life of NAD+: an old metabolite controlling new metabolic signaling pathways. Endocr Rev 31: 194-223. doi: 10.1210/er.2009-0026 PMID: 20007326
32. Karanikas V, Zamanakou M, Kerenidi T, Dahabreh J, Hevas A, Nakou M, et al. (2007) Indoleamine 2,3-dioxygenase (IDO) expression in lung cancer. Cancer Biol Ther 6: 1258-1262. PMID: 17700060
33. von Heideman A, Berglund A, Larsson R, Nygren P (2010) Safety and efficacy of NAD depleting cancer drugs: results of a phase I clinical trial of CHS 828 and overview of published data. Cancer Chemother Pharmacol 65: 1165-1172. doi: 10.1007/s00280-009-1125-3 PMID: 19789873
34. Lorenzen J, Lewis CE, McCracken D, Horak E, Greenall M, McGee JO (1991) Human tumour-associated NK cells secrete increased amounts of interferon-gamma and interleukin-4. Br J Cancer 64: 457-462. PMID: 1911184
35. Alshaker HA, Matalka KZ (2011) IFN-gamma, IL-17 and TGF-beta involvement in shaping the tumor microenvironment: The significance of modulating such cytokines in treating malignant solid tumors. Cancer Cell Int 11:33 doi: 10.1186/1475-2867-11-33 PMID: 21943203
36. Gordon MS, Rosen LS, Mendelson D, Ramanathan RK, Goldman J, Liu L, et al. (2013) A phase 1 study of TRC102, an inhibitor of base excision repair, and pemetrexed in patients with advanced solid tumors. Invest New Drugs 31: 714-723. doi: 10.1007/s10637-012-9876-9 PMID: 23054206
37. Weeks LD, Fu P, Gerson SL (2013) Uracil-DNA glycosylase expression determines human lung cancer cell sensitivity to pemetrexed. Mol Cancer Ther 12: 2248-2260. doi: 10.1158/1535-7163.MCT-13-0172 PMID: 23873851
38. Pallotta MT, Orabona C, Volpi C, Vacca C, Belladonna ML, Bianchi R, et al. (2011) Indoleamine 2,3-dioxygenase is a signaling protein in long-term tolerance by dendritic cells. Nat Immunol 12: 870-878. doi: 10.1038/ni.2077 PMID: 21804557
39. Yoshida N, Ino K, Ishida Y, Kajiyama H, Yamamoto E, Shibata K, et al. (2008) Overexpression of indoleamine 2,3-dioxygenase in human endometrial carcinoma cells induces rapid tumor growth in a mouse xenograft model. Clin Cancer Res 14: 7251-7259. doi: 10.1158/1078-0432.CCR-08-0991 PMID: 19010841
40. Honeywell RJ, Ruiz van Haperen VW, Veerman G, Smid K, Peters GJ (2015) Inhibition of thymidylate synthase by 2',2'-difluoro-2'-deoxycytidine (Gemcitabine) and its metabolite 2',2'-difluoro-2'-deoxyuridine. Int J Biochem Cell Biol 60: 73-81. doi: 10.1016/j.biocel.2014.12.010 PMID: 25562513
41. Yang LY, Li L, Jiang H, Shen Y, PlunkettW(2000) Expression of ERCC1 antisense RNA abrogates gemicitabine-mediated cytotoxic synergism with cisplatin in human colon tumor cells defective in mismatch repair but proficient in nucleotide excision repair. Clin Cancer Res 6: 773-781. PMID: 10741696
42. Shewach DS, Lawrence TS (2007) Antimetabolite radiosensitizers. J Clin Oncol 25: 4043-4050. PMID: 17827452
43. Roy R, Chun J, Powell SN (2012) BRCA1 and BRCA2: different roles in a common pathway of genome protection. Nat Rev Cancer 12: 68-78.
44. Genova C, Rijavec E, Truini A, Coco S, Sini C, Barletta G, et al. (2013) Pemetrexed for the treatment of non-small cell lung cancer. Expert Opin Pharmacother 14: 1545-1558. doi: 10.1517/14656566.2013. 802774 PMID: 23683110
45. Gudmundsdottir K, Ashworth A (2006) The roles of BRCA1 and BRCA2 and associated proteins in the maintenance of genomic stability. Oncogene 25: 5864-5874. PMID: 16998501